Pfizer's search for Paxlovid's COVID-busting sibling leads to low-profile antiviral biotech

Pfizer’s COVID-19 drug Paxlovid has rapidly grown into a $22 billion-a-year mega blockbuster. Now, the Big Pharma wants to develop a sibling to the antiviral—and has identified Clear Creek Bio as an ally that can help make it happen.